Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sharon

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Annals of Surgical Oncology|March 18, 2022
Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma CohortRichard J Straker, Katharine Krupp, Cimarron E Sharon, et al.
Annals of Surgical Oncology|May 19, 2023
Impact of Patient Comorbidities on Presentation Stage of Breast and Colon CancersCimarron E Sharon, Michael Wang, Gabriella N Tortorello, et al.
Journal of the American Academy of Dermatology|March 9, 2018
The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sexAndrew J Sinnamon, Cimarron E Sharon, Yun Song, et al.
Annals of Surgical Oncology|July 26, 2018
Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for MelanomaAndrew J Sinnamon, Yun Song, Cimarron E Sharon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2026
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare CancersS P Patel, M Othus, Y K Chae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanomaC E Sharon, G N Tortorello, K L Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2024
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812]C E Sharon, G N Tortorello, K L Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free SurvivalKevin L Ma, Tara C Mitchell, Meaghan Dougher, et al.
Journal of the American Academy of Dermatology|October 2, 2022
Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort studyAdrienne B Shannon, Cimarron E Sharon, Richard J Straker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Annals of Surgical Oncology|March 18, 2022
Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma CohortRichard J Straker, Katharine Krupp, Cimarron E Sharon, et al.
Annals of Surgical Oncology|May 19, 2023
Impact of Patient Comorbidities on Presentation Stage of Breast and Colon CancersCimarron E Sharon, Michael Wang, Gabriella N Tortorello, et al.
Journal of the American Academy of Dermatology|March 9, 2018
The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sexAndrew J Sinnamon, Cimarron E Sharon, Yun Song, et al.
Annals of Surgical Oncology|July 26, 2018
Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for MelanomaAndrew J Sinnamon, Yun Song, Cimarron E Sharon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2026
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare CancersS P Patel, M Othus, Y K Chae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanomaC E Sharon, G N Tortorello, K L Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2024
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812]C E Sharon, G N Tortorello, K L Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free SurvivalKevin L Ma, Tara C Mitchell, Meaghan Dougher, et al.
Journal of the American Academy of Dermatology|October 2, 2022
Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort studyAdrienne B Shannon, Cimarron E Sharon, Richard J Straker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Pageof 10